These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial. Peris K; Inocencio TJ; Stratigos AJ; Lewis KD; Eroglu Z; Chang ALS; Ivanescu C; Sekulic A; Fury MG; Chen CI; Quek RGW Cancer Med; 2024 Jul; 13(14):e7360. PubMed ID: 39031963 [TBL] [Abstract][Full Text] [Related]
9. Libtayo Gupta AK; Mann A; Vincent K; Abramovits W Skinmed; 2024; 22(2):138-143. PubMed ID: 39090000 [TBL] [Abstract][Full Text] [Related]
10. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Moreno V; Garrido P; Papadopoulos KP; De Miguel Luken MJ; Gil-Martin M; Aljumaily R; Rosen LS; Rietschel P; Mohan KK; Yoo SY; Stankevich E; Lowy I; Fury MG Lung Cancer; 2021 May; 155():151-155. PubMed ID: 33831732 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Yoo SY; Mathias M; Han H; Seebach F; Lowy I; Fury MG; Rischin D Lancet Oncol; 2023 Nov; 24(11):1196-1205. PubMed ID: 37875144 [TBL] [Abstract][Full Text] [Related]
12. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163 [TBL] [Abstract][Full Text] [Related]
14. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979 [TBL] [Abstract][Full Text] [Related]
15. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862 [TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507 [TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V; J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186 [TBL] [Abstract][Full Text] [Related]
18. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360 [TBL] [Abstract][Full Text] [Related]
19. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346 [TBL] [Abstract][Full Text] [Related]
20. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]